Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition

Lorlatinib is a third‐generation, brain‐penetrant anaplastic lymphoma kinase (ALK) and c‐ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) with robust intracranial activity in patients with ALK‐ or ROS1‐positive non‐small cell lung cancer (NSCLC). Data from the ongoing open‐label, single‐arm, mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Steven, Pithavala, Yazdi K., Martini, Jean‐François, Chen, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Pharmacokinetics Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542378/
https://www.ncbi.nlm.nih.gov/pubmed/35373356
http://dx.doi.org/10.1002/jcph.2056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542378/
https://www.ncbi.nlm.nih.gov/pubmed/35373356
http://dx.doi.org/10.1002/jcph.2056

Ejemplares similares